## (Preliminary!) Annual Report

#### Working Group on Cardiovascular Pharmacology and Drug Therapy

#### **Nucleus:**

Chairman:	Faiez Zannad, Nancy, FR
Vice-chairman:	Luis Ruilope, Madrid, SP
Past chairman:	Dan Atar, Oslo, NO
Treasurer:	Keld Kjeldsen, Kobenhavn, DK
Secretary:	Kurt Stoschitzky, Graz, AT
Web editor:	Finn Gustafsson, Kobenhavn, DK
Honorary Senior Advisor	: Ferenc Follath, Zürich, CH
Nucleus Members:	Maria Angeles Alonso Garcia, Madrid, SP
	Wiek van Gilst, Groningen, NL
	Stefan Agewall, Stockholm, SE
	Franco Naccarella, Bologna, IT

#### **VOTES:**

Elections during 2008:

*3 nucleus members have resigned from the nucleus. Online elections have been organised prior to the ESC congress in Munich, with the help of the ESC Office for WGs.* 

## Activities

#### WG Annual Meeting = Endorsed Meeting:

#### Meeting 1:

Cardiovascular Clinical Trialists Forum Name: Chair / organisation committee: Faiez Zannad (Co-organiser: Dan Atar) N° of participants: 800 N° of exhibitors: 20

# Education programme:

#### Training 1:

Name: Educational Autumn Meeting on Advances in Cardiovascular Drug Therapy "Treatment of hyperlipidaemia and diabetes: State of the art 2007" Chair / organisation committee: Kurt Stoschitzky N° of participants: 60 4

N° of exhibitors:

# Publications / Guidelines / Scientific Papers

**Submitted by the WG (not by individuals)** Please specify Topics & Authors (specify if ordinary member or nucleus members)

#### Is your WG officially affiliated to a journal? YES

Editors-in-Chief: Faiez Zannad and Pascal Bousquet Title: Fundamental and Clinical Pharmacology Contribution: Journal affiliated to our Working Group (The Editor [Faiez Zannad] is Chairman of our Working Group)

#### Position Papers / Consensus Documents:

European MEdicines Agency Guideline on the Evaluation of Medicinal Products for Cardiovascular Disease Prevention

#### Participation to guidelines writing / reviewing:

- WG represented in the writing commitee for the 2007 CV-Joint Prevention Guidelines (Dan Atar)
- WG represented in the writing commitee for the 2008 HF-guideline (Dan Atar)
- WG represented in position paper "Bleeding complications in ACS" to be published in 2009 (Dan Atar)

# Accepted Proposals for pre-arranged sessions at the ESC 2008 main congress and/or ESC Sub-specialty meetings

# Sessions at the ESC Congress 2008 in Munich (DE)

This year, 4 accepted sessions were proposed by the Working Group:

#### The odyssey from drug discovery to clinical practice. Chairpersons: M L Simoons (Rotterdam, NL), E Braunwald (Boston, US)

- When basic science is lost in translation. T F Lüscher (Zürich, CH)
- The dilemma implementing trial evidence into clinical practice. T R Pedersen (Oslo, NO)
- We treat individuals, not populations. D Atar (Oslo, NO)
- Current clinical trials are not addressing the real issues. V Fuster (New York, US)

#### The value of surrogate end points in clinical trials Chairpersons: F Follath (Zurich, CH), W H van Gilst (Groningen, NL)

- Intima media thickness. S Agewall (Oslo, NO)
- Atherosclerotic load imaging. R Corti (Zürich, CH)
- Biomarkers. A Maisel (San Diego, US)
- How useful are surrogates in clinical practice? S J Pocock (London, GB)

#### New frontiers in hypertension Chairpersons: K Stoschitzky (Graz, AT), S Taddei (Pisa, IT)

- Vitamin D and hypertension: more light, please. M Hermann (Zürich, CH)
- Renin-angiotensin vaccination. J Nussberger (Lausanne, CH)
- Renin back into the arena. A Danser (Rotterdam, NL)
- Long-term prevention of arterial hypertension: a dream yet to become true. T M MacDonald (Dundee, GB)

#### The safety catch: cardiovascular safety of non-cardiovascular drugs Chairpersons: F Zannad (D.-Les-Toul Cedex, FR), FT Ruschitzka (Zurich, CH)

- Antidiabetic drugs. J G F Cleland (Kingston upon Hull, GB)
- Erythropoietin stimulating agents. H Krum (Melbourne, AU)
- Antiangiogenic and antiinflammatory drugs. F T Ruschitzka (Zürich, CH)
- Dopamine agonists and valvular heart disease. JS Borer (New York, US)

# **Future projects:**

Educational Autumn Meeting, Wien, AT, November 2008

Scandinavian Arrhythmia Spring Meeting, Kobenhavn, DK, June 2009

Cardiovascular Clinical Trialists Forum, Cannes, FR, September 2009

Finances: Balance sheet (September 2008): +EUR 3569,-

Yours sincerely,

Faiez Zannad (Chairman) Kurt Stoschitzky (Secretary) From: Dan Atar [mailto:dan.atar@online.no] Sent: 19. november 2008 16:29 To: 'Kurt Stoschitzky' Cc: Faiez ZANNAD; 'ruilope@ad-hocbox.com' Subject: RE: Antw: RE: Antw: RE: Antw: WG Pharmacology Annual Report2007/08

very nice, thanks Kurt

a few rectifications:

4. regarding the Vote: very important that you fill in what Celine instructed you to,

she gave you a link with all details. Please insert here (if you are in doubt, please ask her directly)

please resend after rectification

thanks

Dan